High-Dose Weekly AmBisome Antifungal Prophylaxis in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Pharmacokinetic Study Parinda.

Slides:

Advertisements

Similar presentations

A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.

Advertisements

Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation Patricia M. Sheean,

Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review

Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns

Norovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation Recipients: Incidence, Risk Factors, and Outcome Joseph Delano F. Robles, Daniel.

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

How to Treat MDS without Stem Cell Transplantation

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

IV Busulfan Dose Individualization in Children undergoing Hematopoietic Stem Cell Transplant: Limited Sampling Strategies L. Lee Dupuis, Cathryn Sibbald,

Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation

Reduced-Intensity Conditioning Hematopoietic Cell Transplantation Is an Effective Treatment for Patients with SLAM-Associated Protein Deficiency/X-linked.

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

Allogeneic Stem Cell Transplantation in Myelofibrosis

Biology of Blood and Marrow Transplantation

Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation Patricia M. Sheean,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Sabina Kersting, Leo F. Verdonck

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Vascular Endothelial Growth Factor and Activin-A Serum Levels Following Allogeneic Hematopoietic Stem Cell Transplantation David Nachbaur, Petra Schumacher,

The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell.

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation

Pharmacogenetic Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplants Ashley Teusink,

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility? Jason W. Chien, Keith M. Sullivan Biology.

Betty T. Tran, Abigail Halperin, Jason W. Chien

Caroline F. Morrison, Donna M

Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J

Stem Cell Transplant for Children with Sickle Cell Anemia: Parent and Patient Interest Michael Roth, Julie Krystal, Deepa Manwani, Catherine Driscoll,

A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model Justin N. Baker,

Controversies in Lymphoma: The Role of Hematopoietic Cell Transplantation for Mantle Cell Lymphoma and Peripheral T Cell Lymphoma Peter Dreger, Ginna.

Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation Ashley Teusink,

Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation Vijaya.

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

Alternate-Day Micafungin Antifungal Prophylaxis in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Pharmacokinetic Study Parinda.

Folinic Acid Supplementation in Higher Doses is Associated with Graft Rejection in Pediatric Hematopoietic Stem Cell Transplantation Henric Lindqvist,

Hemophagocytic Lymphohistiocytosis (HLH) after Hematopoietic Stem Cell Transplant (HSCT) or an Impostor: A Word of Caution! Anant Vatsayan, MD, Linda.

Kamal Kant Singh Abbi, Junting Zheng, Sean M

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Cytokine Profile of Engraftment Syndrome in Pediatric Hematopoietic Stem Cell Transplant Recipients Pooja Khandelwal, Sabine Mellor-Heineke, Najibah.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus- Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients.

Disparity in Survival Outcome after Hematopoietic Stem Cell Transplantation for Hematologic Malignancies According to Area of Primary Residence Keshav.

Shigeo Fuji, Hermann Einsele, Bipin N. Savani, Markus Kapp

Prolonged Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation and Its Association with a Reduction in Ploidy and an Immaturation.

Total and Active Rabbit Antithymocyte Globulin (rATG;Thymoglobulin®) Pharmacokinetics in Pediatric Patients Undergoing Unrelated Donor Bone Marrow Transplantation

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy Special Interest Group Amber B. Clemmons,

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Pauline Damien, David S. Allan

Gerard Socié, K. Scott Baker, Smita Bhatia

Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation Mohammed M. Elayan, Justin G.

What is quality in a transplant program?

Impact of Pharmacogenetics and Therapeutic Drug Monitoring On Optimizing Voriconazole Dosing in Pediatric Patients Undergoing Hematopoietic Cell Transplantation

Participation in Clinical Research: Perspectives of Adult Patients and Parents of Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation

Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab Rebecca A. Marsh, Tsuyoshi Fukuda, Chie Emoto, Lisa Neumeier, Pooja.

Effect of Weight and Maturation on Busulfan Clearance in Infants and Small Children Undergoing Hematopoietic Cell Transplantation Radojka M. Savic, Morton.

Blood and Marrow Transplant Handbook

Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

Mammen Chandy Biology of Blood and Marrow Transplantation

Praveena Narayanan, Alexandra Wolanskyj, Shawna L. Ehlers, Mark R

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Treatment versus Transplant for Challenging Hematologic Disorders

IL-8 Levels Early after Bone Marrow Transplant are Associated with Later Complications of Stem Cell Transplantation Nikhil Dole, Nathan Luebbering, Nicholas.

Mary Eapen Biology of Blood and Marrow Transplantation

In Memoriam: E. Donnall Thomas

Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma Luciano J. Costa, Jia-Xing Huang, Parameswaran.

Optimal Donor Selection: Beyond HLA

Prediction of Area under the Cyclosporine Concentration Versus Time Curve in Children Undergoing Hematopoietic Stem Cell Transplantation L. Lee Dupuis,

Presentation transcript:

High-Dose Weekly AmBisome Antifungal Prophylaxis in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Pharmacokinetic Study Parinda Mehta, Alexander Vinks, Alexandra Filipovich, Gretchen Vaughn, Deborah Fearing, Christine Sper, Stella Davies Biology of Blood and Marrow Transplantation Volume 12, Issue 2, Pages 235-240 (February 2006) DOI: 10.1016/j.bbmt.2005.10.010 Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Pharmacokinetic profiles for week 1 and week 4 (mean ± SD): Mean concentration–time profiles of nonliposomal amphotericine B in pediatric HSCT patients. Mean data points (±SD) are graphically connected for each course of therapy in week 1 and week 4. Biology of Blood and Marrow Transplantation 2006 12, 235-240DOI: (10.1016/j.bbmt.2005.10.010) Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Correlation between body weight and volume of distribution (Vz): Correlation plot of individual estimates for volume of distribution (in L) versus body weight (WT in Kg). The solid line is the line of best fit for the data (R2 = .55). The dashed line represents the 95% confidence intervals. Biology of Blood and Marrow Transplantation 2006 12, 235-240DOI: (10.1016/j.bbmt.2005.10.010) Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Correlation between body weight and clearance (CL): Correlation plot of individual estimates for clearance (in L/h) versus body weight (WT in Kg). The solid line is the line of best fit for the data (R2 = .19, not significant). The dashed line represents the 95% confidence intervals. Biology of Blood and Marrow Transplantation 2006 12, 235-240DOI: (10.1016/j.bbmt.2005.10.010) Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions